Prevention of murine collagen‐induced arthritis in the knee and ipsilateral paw by local expression of human interleukin‐1 receptor antagonist protein in the knee
Open Access
- 1 May 1997
- journal article
- basic science
- Published by Wiley in Arthritis & Rheumatism
- Vol. 40 (5) , 893-900
- https://doi.org/10.1002/art.1780400517
Abstract
Objective. To determine the efficacy of local human interleukin-1 receptor antagonist (HuIL-1Ra) gene therapy in murine collagen-induced arthritis (CIA). Methods. DBA/1 mice were immunized against bovine type II collagen. Before the onset of arthritis, NIH/3T3 fibroblasts transfected with pMFG-IRAP were transplanted into the knee cavity. Normal NIH/3T3 cells served as controls. Paws were evaluated macroscopically for redness, swelling, and deformities during the course of arthritis. Swelling of the knee joints was measured by external gamma counting of 99mtechnetium accumulation in the joint. Paws and knee joints were dissected and processed for histologic studies to evaluate inflammation and cartilage destruction. Results. The NIH/3T3 fibroblasts survived in the joint cavity of DBA mice for at least 7 days. The transduced cells expressed immunoreactive and bioactive HuIL-1Ra in the knee joint, and produced sufficient amounts to block the effect of 1 ng of recombinant murine IL-1α on chondrocyte proteoglycan synthesis. The onset of CIA was almost completely prevented in knee joints containing HuIL-1Ra-producing cells, whereas joints containing normal cells showed severe inflammation and destruction of cartilage. Moreover, onset of CIA in the draining joints (ipsilateral paws) of the HuIL-1Ra gene-bearing knees was also prevented. Conclusion. Local production of HuIL-1Ra in the knee was able to ameliorate the effects of IL-1 on cartilage and could prevent the onset of CIA not only in that knee, but also in the “draining” paw. This indicates the feasibility of gene transfer as a therapeutic approach to modulating arthritis.Keywords
This publication has 17 references indexed in Scilit:
- Dose‐range and dose‐frequency study of recombinant human interleukin‐1 receptor antagonist in patients with rheumatoid arthritisArthritis & Rheumatism, 1996
- INTERLEUKIN-1β CONVERTING ENZYME INHIBITION BLOCKS PROGRESSION OF TYPE II COLLAGEN-INDUCED ARTHRITIS IN MICECytokine, 1996
- Anticytokine treatment of established type II collagen–induced arthritis in DBA/1 mice: A comparative study using anti‐TNFα, anti–IL‐1α/β, and IL‐1RaArthritis & Rheumatism, 1996
- Role of interleukin‐1, tumor necrosis factor α, and interleukin‐6 in cartilage proteoglycan metabolism and destruction effect of in situ blocking in murine antigen‐ and zymosan‐induced arthritisArthritis & Rheumatism, 1995
- Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritisThe Lancet, 1994
- Accelerated onset of collagen-induced arthritis by remote inflammationClinical and Experimental Immunology, 1994
- Synovial interleukin‐1 receptor antagonist and interleukin‐1 balance in rheumatoid arthritisArthritis & Rheumatism, 1994
- Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatmentClinical and Experimental Immunology, 1994
- Induction of an acute erosive monarticular arthritis in mice by interleukin‐1 and methylated bovine serum albuminArthritis & Rheumatism, 1990
- Enzyme histochemical reactions in unfixed and undecalcified cryostat sections of mouse knee joints with special reference to arthritic lesionsHistochemistry and Cell Biology, 1986